NEW YORK – Bruker said Tuesday it is acquiring Austrian metabolomics firm Biocrates Life Sciences for an undisclosed amount.

纽约——布鲁克公司周二表示，将以未公开的金额收购奥地利代谢组学公司Biocrates Life Sciences。

The acquisition adds to Bruker's mass spec-based metabolomics offerings and supports its continued expansion into multiomics, building on prior acquisitions of firms in the proteomics space including

这次收购增强了布鲁克基于质谱的代谢组学产品，并支持其继续向多组学领域的扩展，建立在之前对蛋白质组学领域公司收购的基础之上，包括

PreOmics

蛋白组学前处理

and

和

Biognosys

百欧诺思

, the company said.

公司表示。

Biocrates' metabolomics kits cover more than 1,000 metabolites from more than 40 metabolite classes. Its metabolomics technology platform combines sample preparation, metabolite identification, and data analysis.

Biocrates的代谢组学试剂盒涵盖了来自40多种代谢物类别的1000多种代谢物。其代谢组学技术平台结合了样品制备、代谢物鉴定和数据分析。

'Multiomics is the cornerstone for the future of life sciences, biopharma R&D, and clinical research, and Biocrates adds key metabolomics solutions to the Bruker portfolio,' Oliver Rinner, Bruker's VP for enabling multiomics solutions and founder and CEO of Biognosys, said in a statement. 'With our services, software, and kits for high-end proteomics and metabolomics we can now support customers with a truly integrated multiomics approach.'.

“多组学是生命科学、生物制药研发和临床研究未来发展的基石，而Biocrates为布鲁克的产品组合增添了关键的代谢组学解决方案，”布鲁克负责多组学解决方案的副总裁、Biognosys创始人兼首席执行官奥利弗·林纳在一份声明中表示。“通过我们高端蛋白质组学和代谢组学的服务、软件和试剂盒，我们现在可以以真正整合的多组学方法支持客户。”

'What makes this partnership so powerful is our shared passion for multiomics technologies and Biocrates’ continued commitment to supporting and innovating across multiple MS technologies and vendors,' Biocrates CEO Moritz Seuster said in a statement. 'With Bruker we’re poised to scale our impact while staying true to our mission to make omics quantitative, reproducible, and easily accessible.'.

“这一合作之所以如此强大，是因为我们对多组学技术有着共同的热情，并且Biocrates始终致力于支持和创新多种质谱技术及供应商，”Biocrates首席执行官莫里茨·塞乌斯特在一份声明中表示。“通过与布鲁克合作，我们准备扩大影响力，同时忠实于我们的使命，即使组学变得可量化、可重复且易于获取。”